New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
06:31 EDTKPTIKaryopharm reports FY13 EPS ($5.59), may not compare to consensus ($2.93)
Net loss includes stock-based compensation expense of $3.8M and $653,000 for the years ended December 31, 2013 and 2012, respectively.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
07:15 EDTKPTIKaryopharm expects existing cash will fund R&D programs into 2018
Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into 2018, including moving registration-directed clinical studies to their next data inflection points. Karyopharm expects to end 2015 with greater than $200M in cash, cash equivalents and investments.
07:13 EDTKPTIKaryopharm reports Q4 EPS (79c), consensus (65c)
Reports Q4 revenue $16,000, consensus $40,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use